Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label study of PF-08046050 in advanced solid tumors
jRCT2031260208Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of PF-08046050 in colorectal cancer (CRC), gastric cancer (GC), gastroesophageal junction adenocarcinoma and 2 more, sponsored by Pfizer. Primary endpoints: Number of participants with adverse events, Number of participants with laboratory abnormalities and 3 more. Started Jun 2026; status: recruiting.
02
Drugs
PF-08046050
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)gastroesophageal junction adenocarcinomanon-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031260208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260208.